CN101236195A - Hematological analyzer, method for analyzing body fluid and control system thereof - Google Patents
Hematological analyzer, method for analyzing body fluid and control system thereof Download PDFInfo
- Publication number
- CN101236195A CN101236195A CNA2008100052392A CN200810005239A CN101236195A CN 101236195 A CN101236195 A CN 101236195A CN A2008100052392 A CNA2008100052392 A CN A2008100052392A CN 200810005239 A CN200810005239 A CN 200810005239A CN 101236195 A CN101236195 A CN 101236195A
- Authority
- CN
- China
- Prior art keywords
- leucocyte
- sample
- mensuration
- measure
- humoral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 51
- 239000010839 body fluid Substances 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 20
- 230000002489 hematologic effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 claims abstract description 65
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 43
- 230000003287 optical effect Effects 0.000 claims abstract description 41
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 40
- 238000004458 analytical method Methods 0.000 claims abstract description 28
- 210000004369 blood Anatomy 0.000 claims description 50
- 239000008280 blood Substances 0.000 claims description 49
- 238000002360 preparation method Methods 0.000 claims description 42
- 210000001616 monocyte Anatomy 0.000 claims description 31
- 239000012530 fluid Substances 0.000 claims description 18
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 16
- 230000002380 cytological effect Effects 0.000 claims description 12
- 206010048612 Hydrothorax Diseases 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 210000003617 erythrocyte membrane Anatomy 0.000 claims description 10
- 206010003445 Ascites Diseases 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 7
- 238000005286 illumination Methods 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 210000003516 pericardium Anatomy 0.000 claims description 3
- 210000003567 ascitic fluid Anatomy 0.000 claims description 2
- 230000008033 biological extinction Effects 0.000 claims description 2
- 230000031700 light absorption Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 abstract description 37
- 238000004590 computer program Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 141
- 238000010586 diagram Methods 0.000 description 38
- 239000002245 particle Substances 0.000 description 33
- 238000012545 processing Methods 0.000 description 33
- 210000003743 erythrocyte Anatomy 0.000 description 28
- 238000001514 detection method Methods 0.000 description 16
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 238000005070 sampling Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000009826 distribution Methods 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 8
- 238000004820 blood count Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 6
- 238000007405 data analysis Methods 0.000 description 6
- 239000003219 hemolytic agent Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 210000003924 normoblast Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/1031—Investigating individual particles by measuring electrical or magnetic effects
- G01N15/12—Investigating individual particles by measuring electrical or magnetic effects by observing changes in resistance or impedance across apertures when traversed by individual particles, e.g. by using the Coulter principle
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00584—Control arrangements for automatic analysers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/012—Red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/012—Red blood cells
- G01N2015/014—Reticulocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a hematological analyzer including a measurement mode setting unit sets a body fluid measurement mode; a measurement start instruction unit receives a measurement start instruction; a optical information obtaining unit irradiates a measurement sample with light and obtains optical information from cells contained in the measurement sample; and a analysis unit classifies at least white blood cells and nucleated cells other than white blood cells contained in the measurement sample, and counts the white blood cells and nucleated cells other than white blood cells based on the optical information obtained from the cells in the measurement sample prepared from a body fluid sample and white blood cell measuring reagent when the body fluid measurement mode has been set and the measurement start instruction has been selected. A method for analyzing body fluid and a computer program product are also disclosed.
Description
Technical field:
The present invention relates to a kind ofly can not only measure blood, also can measure cellanalyzer, method for analyzing body fluid and the control system thereof of other body fluid beyond the blood such as cerebrospinal fluid (marrow liquid), hydrothorax (liquor pleurae) and ascites as sample.
Background technology:
One of in the clinical examination field, cellanalyzer commonly used is that tested sample is analyzed with the blood that picks up from health, and the reference that this analysis result is monitored as diagnosis and treatment.
Simultaneously, blood body fluid in addition such as cerebrospinal fluid are thirsted for measuring easily in the clinical examination field.Usually contain cell hardly in the body fluid, but when ill or tumour is arranged and when damaging, will find hemorrhage (haemocyte) and cells such as abnormal cell, bacterium about organ.
Recorded and narrated on No. 2003/0215890 communique of U.S. Patent Application Publication about measure the technology of the cell in the body fluid with cellanalyzer.Record and narrate on No. 2003/0215890 communique of U.S. Patent Application Publication in view of the above, the reagent composition that will contain aldehyde, surfactant and cyclodextrin mixes with cerebrospinal fluid (CSF), the formation determination sample, analyze made mensuration sample with the ADVIA120 cytoanalyze, according to the cell in classification of cytological map shown in Figure 11 A～Figure 11 G of this communique and the counting cerebrospinal fluid.
Yet,, in fact only analyze cerebrospinal fluid (CSF), about not analyzing as body fluid such as ascites and hydrothorax as body fluid according to disclosed technology on No. 2003/0215890 communique of U.S. Patent Application Publication.Usually scarcely contain haemocyte particle composition in addition in the cerebrospinal fluid, and in the body fluid beyond the cerebrospinal fluid such as ascites and hydrothorax, because of patient disease contains middle chrotoplast, macrophage and tumour cell etc. sometimes.Like this, when disclosed technical Analysis contains the body fluid of haemocyte particle composition in addition on No. 2003/0215890 communique of utilization U.S. Patent Application Publication, just might cause such as certain cell compartment haemocyte particle composition in addition to occur, can't draw correct analysis result's problem at cytological map.
Summary of the invention:
Scope of the present invention is not limit by the statement of this joint summary of the invention on any degree only by appended claim book defined.
The cellanalyzer of the mensuration haemocyte that the present invention first side provides comprises: the mode determination setup unit is used to set the humoral determination pattern; Measure the beginning indicating member, be used to accept the indication that begins to measure; The optical information acquiring unit, sample is measured in illumination, obtains optical information from the contained cell of this mensuration sample; Analytic unit, behind above-mentioned humoral determination mode initialization, when said determination begins indicating member when receiving the indication that begins to measure, according to the above-mentioned optical information of obtaining in the said determination sample of measuring by humoral specimen and leucocyte with reagent preparation, the contained cell of this mensuration sample is categorized as leucocyte and leucocyte karyocyte in addition at least, to the counting of the karyocyte beyond leucocyte and the leucocyte.
Described analytic unit is divided into multinuclear leucocyte and monocyte with leucocyte, respectively to multinuclear leucocyte and monocyte counting.
Described analytic unit calculates multinuclear leucocyte shared ratio or monocyte shared ratio in leucocyte in leucocyte.
Obtain full karyocyte number the karyocyte number of described analytic unit beyond leukocyte count and leucocyte, obtain the leucocyte karyocyte in addition and the ratio of full karyocyte again.
Described analytic unit is further told erythrocyte ghost with the contained cell of described mensuration sample.
When not setting described humoral determination pattern, after the indication that mensuration beginning indicating member is accepted to begin to measure, analytic unit is several subclass according to the described optical information of obtaining the mensuration sample with reagent preparation from blood preparation and leucocyte mensuration with the contained leukocyte differential count of described mensuration sample, and counting.
Also possess output unit, be used to export the display frame of the analysis result that shows described analytic unit.
Described optical information is selected from scattered light information, the fluorescence information that cell sends, the light absorption information of cell extinction and the combination of these information that cell sends.
Described humoral specimen is selected from the dislysate that comprises cerebrospinal fluid, hydrothorax, ascites, pericardium liquid, joint fluid, peritoneal dialysis and the liquid of intraperitoneal cleaning fluid.
Described karyocyte is selected from by macrophage, middle chrotoplast, tumour cell, erythrocyte ghost and the colony that constitutes thereof.
The cellanalyzer that the present invention second side provides comprises: the mode determination setup unit is used to set the humoral determination pattern; Measure the beginning indicating member, be used to accept the indication that begins to measure; The aspirating specimen unit is used for inhaling and moves sample; Measure the specimen preparation unit, inhale the sample and the leucocyte mensuration of moving with the aspirating specimen unit and measure sample with reagent preparation; The optical information acquiring unit, sample is measured in illumination, obtains optical information from the contained cell of this mensuration sample; Analytic unit according to the above-mentioned optical information of obtaining, is classified to the contained cell of said determination sample, and the above-mentioned cell count to classifying.After above-mentioned humoral determination pattern is set by said determination mode initialization unit, when said determination begins indicating member when receiving the indication that begins to measure, said determination specimen preparation unit is just inhaled the humoral specimen and the above-mentioned leucocyte that move by above-mentioned aspirating specimen unit and is measured with reagent preparation said determination sample, above-mentioned analytic unit is according to the above-mentioned optical information of obtaining from the said determination sample, contained cytological classification is leucocyte and leucocyte cell in addition in the sample with measuring, and to the counting of the karyocyte beyond leucocyte and the leucocyte.
When not setting described humoral determination pattern, after the indication that mensuration beginning indicating member is accepted to begin to measure, described mensuration specimen preparation unit is inhaled the blood preparation and the described leucocyte mensuration of moving with described aspirating specimen unit and is measured sample with reagent preparation, described analytic unit is several subclass according to the described optical information of obtaining from described mensuration sample with the contained leukocyte differential count of described mensuration sample, and counting.
The method for analyzing body fluid that the present invention the 3rd side provides comprises: (a) step: set mode determination, so that set the humoral determination pattern; (b) step: behind the humoral determination mode initialization, accept the indication that begins to measure; (c) step: after accepting the above-mentioned indication that begins to measure, measure the mensuration sample of using reagent preparation by humoral specimen and leucocyte, from the contained cell of this mensuration sample, obtain optical information with rayed; (d) step: according to the above-mentioned optical information of obtaining, the contained cell of said determination sample is categorized as karyocyte beyond leucocyte and the leucocyte at least, and to karyocyte counting beyond leucocyte and the leucocyte.
Described method for analyzing body fluid also comprises (e) step: after accepting the described indication that begins to measure, inhale and move described humoral specimen, and measured with the described mensuration sample of reagent preparation by described humoral specimen and described leucocyte that suction moves.
Described (d) step comprises that with leukocyte differential count be multinuclear leucocyte and monocyte and step that multinuclear leucocyte and monocyte are counted respectively.
Described (d) step comprises the step of monocyte ratio in the multinuclear leucocyte ratio asked in the leucocyte or the leucocyte.
The present invention the 4th side provides a kind of control system of body fluid analysis instrument, comprising: a kind of mode determination setting control system, set mode determination, so that set the humoral determination pattern; Control system is accepted in a kind of mensuration indication, behind the humoral determination mode initialization, accepts the indication that begins to measure; A kind of optical information is obtained control system, accept the above-mentioned indication that begins to measure after, measure mensuration sample with rayed by humoral specimen and leucocyte with reagent preparation, from the contained cell of this mensuration sample, obtain optical information; And a kind of cytological classification and counting control system, according to the above-mentioned optical information of obtaining, the contained cell of said determination sample is categorized as leucocyte and leucocyte karyocyte in addition at least, and to the counting of the karyocyte beyond leucocyte and the leucocyte.
Described cytological classification and counting control system can be multinuclear leucocyte and monocyte with leukocyte differential count and multinuclear leucocyte and monocyte counted respectively.
Described cytological classification and counting control system can calculate monocyte ratio in multinuclear leucocyte ratio in the leucocyte or the leucocyte.
Described cytological classification and counting control system can further be told erythrocyte ghost from the contained cell of described mensuration sample.
Description of drawings:
Fig. 1 is the outside drawing of the cellanalyzer of an embodiment of the present invention.
Fig. 2 is the block diagram of analysis-e/or determining device.
Fig. 3 is the block diagram of fluid device.
Fig. 4 is the optical system displayed map of leucocyte detecting device.
Fig. 5 is the displayed map of RBC/PLT detecting device.
Fig. 6 is the displayed map of HGB detecting device.
Fig. 7 measures the process flow diagram of handling for sample.
Fig. 8 is the accompanying drawing that is used to set the display frame of mode determination.
The process flow diagram that Fig. 9 handles for presequence.
Figure 10 is for measuring the mode chart of being used the scatter diagram of measuring sample by the DIFF of body fluid preparation.
Figure 11 is the cellanalyzer measurement result of embodiment and the comparison diagram of antithetic measurement result.
Figure 12 is for measuring the mode chart of being used the scatter diagram of measuring sample by the DIFF of blood preparation.
Figure 13 is the display frame of the measurement result of blood measuring pattern.
Figure 14 is the display frame of the measurement result of humoral determination pattern.
Figure 15 is the display frame of the measurement result of humoral determination pattern.
Figure 16 is the display frame of the measurement result of humoral determination pattern.
Figure 17 is the blank affirmation picture that detects of beginning shown under the humoral determination pattern.
Embodiment:
The specific embodiment of the present invention below is described with reference to the accompanying drawings.
Figure 1 shows that cellanalyzer 1.This cellanalyzer 1 is as the multinomial Automatic Blood Cell Analyzer that is used for blood test, can measure the blood preparation of specimen container (heparin tube) lining, obtain the characteristic information of contained haemocyte feature in the expression sample, and this characteristic information is carried out analyzing and processing.This cellanalyzer 1 can also analysing body fluid.At the cellanalyzer of present embodiment, analytic target body fluid refers to the endoceliac coelomic fluid that is present in beyond the blood.The hydrops of the ventricles of the brain and subarachnoid space), hydrothorax (liquor pleurae, PE: pleural effusion), ascites (seroperitoneum), pericardium liquid (chambers of the heart hydrops), joint fluid (synovia: the liquid in joint, bursa synovialis and the stndon sheath) etc. specifically refer to cerebrospinal fluid (marrow liquid, CSF:.The dislysate of peritoneal dialysis (CAPD) and intraperitoneal cleaning fluid etc. also can be used as a kind of of body fluid and analyze.Usually almost do not have cell in these liquid, but when ill or relevant organ has tumour and damaged, just may contain cells such as haemocyte, abnormal cell and bacterium.Such as cerebrospinal fluid, from analysis result, can make following clinical deduction.Such as, if red blood cell increases, then may be subarachnoid hemorrhage, if neutrophil cell increases, then suspicious be meningitis, if acidophic cell increases, then can suspect and suffer from infectious diseases (parasite and fungi),, then can suspect to be tuberculosis meningitis and viral meningitis if monocyte increases, if other cells increase, then can suspect for tumour and shift to meninges.As for ascites and hydrothorax etc., if karyocytes such as middle chrotoplast, macrophage and tumour cell are also contained in the dehematize extracellular, just can be used as the index of suspecting diseases such as cancer, by analyzing this haemocyte karyocyte in addition, can obtain these indexs.
Fig. 2 is the block diagram of the determinator 2 of cellanalyzer 1.As shown in Figure 2, determinator 2 comprise haemocyte test section 4, analogue signal processor 5, microcomputer 6, the display operation part 7 that the output signal (simulating signal) of test section 4 is handled and the device for mechanical part 8 of measuring blood and body fluid.Device for mechanical part 8 comprises following fluid device 81.
Fig. 3 is the structured flowchart of fluid device 81.As shown in Figure 3, fluid device 81 comprises aspirating specimen mouth 18, several reagent containers 11, sampling valve 12 and reaction warehouse 13～17.Aspirating specimen mouth 18 is inhaled from specimen container and is moved sample, and this sample is sent to sampling valve 12.Sampling valve 12 is divided into a certain amount of some five equilibriums with the sample that imports.It is different because of mode determination (each mode determination) that this cuts apart number, and the CBC type specimen of measuring RBC number, leukocyte count, platelet count and hemoglobin concentration is divided into trisection.The CBC+DIFF pattern that on above-mentioned CBC mode determination, adds leucocyte five classification again, then sample quadrisection.On CBC+DIFF mensuration project, add the CBC+DIFF+RET pattern of measuring granulophilocyte again, be divided into five five equilibriums.Equally, adding erythroblast on the mensuration project of CBC+DIFF pattern again, to measure the CBC+DIFF+NRBC pattern of project also be that sample is divided into five five equilibriums.On CBC+DIFF pattern+RET mensuration project, add the CBC+DIFF+RET+NRBC pattern of measuring erythroblast again, then be divided into six five equilibriums.Above mode determination is the blood measuring pattern of measuring blood entirely.At last, in the humoral determination pattern of measuring body fluid, sample is divided into bisection.
Reagent (dilution) imports this sampling valve 12 from reagent container 11, and the sample five equilibrium of being cut apart is transported to reaction warehouse 13～17 and aftermentioned HGB detecting device 43 with reagent.A certain amount of sample (five equilibrium), a certain amount of dilution and a certain amount of dyeing liquor that reaction warehouse 13 provides sampling valve 12 to extract by no illustrated fixed displacement pump, these samples and reagent are prepared the mensuration sample of leucocyte four classification (DIFF) usefulness through mixing.
As dilution, the reagent " leucocyte hemolysin STROMATOLYSER-4DL " that can suitably use SYSMEX Co., Ltd to provide.This reagent contains surfactant, can lysed erythrocyte.The reagent " leucocyte four classification liquid STROMATOLYSER-4DS " that dyeing liquor can suitably use SYSMEX Co., Ltd to provide equally.This dyeing liquor contains ethylene glycol, low alcohol, polymethine, and behind above-mentioned dilution haemolysis, the haemocyte composition is colored, and finally produces 50 times of dilution samples.
If select the body fluid mode determination, then prepare leukocyte differential count with the mensuration sample with the condition of measuring the same specimen amount of sample, same reagent and same amount of reagent with leucocyte four classification therewith.But as described later, the leukocyte differential count leucocyte of humoral determination pattern is not four classes, but two classes.
A certain amount of sample, a certain amount of dilution hemolytic agent and a certain amount of dyeing liquor that reaction warehouse 14 provides sampling valve 12 to gather by no illustrated fixed displacement pump with these samples and reagent mix, are manufactured with nucleated red blood cell (NRBC) and measure with measuring sample.
A certain amount of sample, a certain amount of dilution hemolytic agent and a certain amount of dyeing liquor that reaction warehouse 15 provides sampling valve 12 to gather by no illustrated fixed displacement pump with these samples and reagent mix, are made granulophilocyte (RET) and are measured with measuring sample.
A certain amount of sample and a certain amount of dilution hemolytic agent that reaction warehouse 16 provides sampling valve 12 to gather by no illustrated fixed displacement pump with these samples and reagent mix, are made leucocyte and basicyte (WBC/BASO) and are measured with measuring sample.
A certain amount of sample, a certain amount of dilution that reaction warehouse 17 provides sampling valve 12 to gather by no illustrated fixed displacement pump with these samples and reagent mix, are made red blood cell/blood platelet (RET/PLT) and are measured with measuring sample.
In addition, a certain amount of sample, a certain amount of dilution hemolytic agent of sampling valve 12 collections are also supplied aftermentioned HGB detecting device 43.
There is the leukocytic leucocyte detecting device 41 of detection test section 4.This leucocyte detecting device 41 also is used for the detection of erythroblast and granulophilocyte.The RBC/PLT detecting device 42 and the HGB detecting device 43 of measuring hemochrome amount in the blood of RBC number and platelet count measured in addition in test section 4 except that leucocyte detecting device 41.
Above-mentioned leucocyte detecting device 41 mainly is made of fluorescence detector, particularly, is made of the detecting device that uses flow cytometry.At this, so-called cell art is promptly measured physical property and the chemical property that cell and other biological are learned particle, and so-called flow cytometry refers to: allow these particles from thread by, carry out method for measuring.Figure 4 shows that the optical system of leucocyte detecting device 41.In the figure, the light beam that penetrates from lasing fluorescence diode 401 shines haemocyte in the sheath flow pool 403 of flowing through by collimating mirror 402.This leucocyte detecting device 41 detects forward scattering light intensity, lateral scattering light intensity and the side direction fluorescence intensity that the haemocytes in sheath flow pools 403 are sent under laser radiation, with this as the haemocyte characteristic parameter.
At this, scattering of light is because this particle of haemocyte becomes barrier on the direct of travel of light, the phenomenon that light therefore changes its direct of travel and produced.Detect the particle characteristics information that this scattered light can obtain relevant particle size and composition.Forward scattering only refer to particle that send with the essentially identical scattered light of direct of travel institute's irradiation light.Can obtain the characteristic information of relevant particle (haemocyte) size from the forward direction scattered light.Lateral scattering only particle send with institute irradiation light scattered light slightly in vertical direction.Can obtain the characteristic information of relevant particle inside from side scattered light.When laser radiation was to the haemocyte particle, the lateral scattering light intensity depended on the complicacy (quantity of the shape of nuclear, size, density and particle) of cell interior.Therefore, utilize this characteristic of lateral scattering light intensity (discriminating) haemocyte of can classifying, and measure haemocyte quantity.In addition, stated present embodiment and taked to use forward scattering light and side scattered light structure as scattered light, but be not limited thereto, so long as can obtain to analyze the scattered light signal of needed reflection particle characteristics, scattered light is not limit through the angle of the optical axis of the light of sheath flow pool irradiation for light source.
Illumination is then sent than the longer light of institute's irradiation wave-wave such as the sort of fluorescent material of dyed haemocyte.Fluorescence intensity is to dye good more by force more, measures the characteristic information that this fluorescence intensity just can obtain relevant blood cell staining degree.Therefore, poor according to (side direction) fluorescence intensity can be to leucocyte mensuration such as classify.
As shown in Figure 4, the forward scattering light that the haemocyte (leucocyte and erythroblast) of sheath flow pool 403 sends of flowing through is accepted by light emitting diode (forward scattering light optical collector) 406 by condenser 404 and pin hole 405.Side scattered light is accepted by photomultiplier (side scattered light optical collector) 411 by condenser 407, dichronic mirror 408, blooming 409 and pin hole 410.Side direction fluorescence is accepted by photomultiplier (side direction fluorescence optical collector) 412 by condenser 407 and dichronic mirror 408.From the suffered light signals of each optical collector 406,411 and 412 outputs amplify by the analogue signal processor 5 that constitutes by amplifier 51,52,53 etc. respectively and analog signal processing such as waveform processing after, be transported to microcomputer 6.
Below, describe with regard to the structure of RBC/PLT detecting device 42.Fig. 5 is the brief configuration mode chart of RBC/PLT detecting device 42.RBC/PLT detecting device 42 can use sheath stream DC detection method to measure RBC number and platelet count.RBC/PLT detecting device 42 has sheath flow pool 42a as shown in Figure 5.This sheath flow pool 42a is provided with the application of sample mouth 42b of upward opening, and sample can add this application of sample mouth 42b from reaction warehouse 17.The sheath flow pool 42a tapered taper sample storehouse 42c that makes progress in addition, above-mentioned application of sample mouth 42b just is configured in the central interior of this sample storehouse 42c.42c upper end in sample storehouse is provided with hole 42d, and this hole 42d is just in time relative with application of sample mouth 42b center.The mensuration sample that confession sample device provides upwards transports from the front end of application of sample mouth 42b, and meanwhile, preceding sheath fluid is fed to sample storehouse 42c, and preceding sheath fluid upwards flows to hole 42d.At this, measure the encirclement current downflow of sample at preceding sheath fluid, taper sample storehouse 42c attenuates the mensuration sample stream, and the haemocyte of measuring in the sample passes through hole 42d one by one.Hole 42d establishes electrode, supplies to have DC current between this electrode.Detect the variation of the direct current resistance of hole 42d when measuring sample stream via hole 42d, this electric signal is outputed to controller 25.Above-mentioned direct current resistance can increase during by hole 42d at haemocyte, and therefore, this electric signal reflection haemocyte is by the information of hole 42d, by this electric signal is carried out signal Processing, to red blood cell and platelet count.
The top of hole 42d is provided with the recovery tube 42e that extends up and down.This recovery tube 42e is disposed at by in hole 42d and the sample storehouse 42f that sample storehouse 42c links to each other.Separate with sample storehouse 42f inwall recovery tube 42e lower end.Sample storehouse 42f has back sheath fluid to provide, and after this sheath fluid flows downward along the exterior lateral area of the recovery tube 42e of sample storehouse 42f.After the back sheath fluid that flows through from the recovery tube 42e outside arrives 42f lower end, sample storehouse, between the inwall by recovery tube 42e lower end and sample storehouse 42f, flow to recovery tube 42e inside.Therefore can prevent to reflux, thereby prevent the flase drop of haemocyte by the haemocyte of hole 42d.
Structure with regard to HGB detecting device 43 describes below.HGB detecting device 43 can be measured hemochrome amount (HGB) by SLS haemoglobin method.Fig. 6 is the oblique view of HGB detecting device 43 structures.HGB detecting device 43 has the sample pond 43a of dress dilution sample, to the luminous light emitting diode 43b of sample pond 43a with receive the light collecting element 43c of the transmitted light that sees through sample pond 43a.Sampling valve 12 quantitative blood dilute preparation dilution sample by the diluted liquid of certain dilution rate and certain hemolytic agent.This hemolytic agent has the character that the haemoglobin in the blood is converted to the SLS-haemoglobin.This dilution sample feeds to sample pond 43a, deposits in sample pond 43a.Under this state, make light emitting diode 43b luminous, transmitted light is received by the light collecting element 43c every the relative configuration with light emitting diode 43b of sample pond 43a.Light emitting diode wavelength light that 43b sends out is easy to be absorbed by the SLS-haemoglobin, and sample pond 43a makes by the high plastic material of light transmission, and therefore, light collecting element 43c receives is transmitted light after the only diluted sample of light emitting diode 43b emission light absorbs.Light collecting element 43c will transport to microcomputer 6 with the corresponding electric signal of light harvesting amount (absorbance), and microcomputer 6 compares the absorbance of this absorbance with the only dilution of measuring in advance, calculates the haemoglobin value.
Operation with regard to the cellanalyzer 1 of present embodiment describes below.Fig. 7 is the process flow diagram of the sample analyzer operation of present embodiment.User (operating personnel) connects the power supply (step S1) of cellanalyzer 1, starts cellanalyzer 1.This cellanalyzer 1 carries out self check (step S2) earlier when starting.In self check, not only test the ruuning situation of respectively moving mechanical part of microcomputer 6, inspection cellanalyzer 1, the blank of also measuring the blank sample that does not contain sample detects.Then, 6 pairs of mode determinations of microcomputer carry out initial setting (step S3).This initial set value is the CBC+DIFF pattern.Particularly, in the processing of step S3, set to measure the parameter (service condition) of blood, as used reaction warehouse and minute setting etc.So, the sample analyzer of present embodiment is the initial launch pattern with the blood measuring pattern.In view of the above, cellanalyzer 1 is in and can accepts the holding state that begins to measure.The picture (step S4) of microcomputer 6 display notification holding state on LCD.
Under this holding state, operating personnel can be switched mode determination by operation display operation part 7.Fig. 8 is for setting the input image mode figure of mode determination.There are mark this shop 120, sample to put into schema category 121, subitem detection (mode determination) kind 122 and species of samples 123 each display frames in this picture.Sample is put into pattern and is provided with three kinds of patterns: operating personnel manually insert specimen container the manual mode that aspirating specimen mouth 18 carries out aspirating specimen; Operating personnel are in advance with sample and reagent mix formation determination sample, inhale the pre-dilution mode of Trace Blood of moving this mensuration sample with aspirating specimen mouth 18; The closed mode of sample is provided by the conveyer that transports specimen container automatically.As species of samples, be provided with normal blood sample routine (Normal), HPC (hemopoietic progenitor cell) sample (HPC) and body fluid (Body Fluid).Operating personnel can specify sample to put into pattern, mode determination and species of samples respectively.If operating personnel specify the blood measuring pattern, then species of samples is appointed as routine (Normal), specify any sample to put into pattern and mode determination again.If specify the humoral determination pattern, then operating personnel specify " manual mode " in the pattern of putting into respectively, one of in subitem detects, specify among " CBC+DIFF ", " CBC+DIFF+RET ", " CBC+DIFF+NRBC " and " CBC+DIFF+NRBC+RET ", in species of samples, specify body fluid (Body Fluid).In step S4, operating personnel so specify desirable mode determination.Carry out blood measuring (selecting N) if operating personnel do not change the mode determination of initial setting, then assign to begin to measure and indicate by the beginning switch at step S5.Microcomputer 6 receives and begins to measure indication (step S6), inhales from the aspirating specimen mouth and moves blood preparation (step S7).
After blood preparation was inhaled and moved, sample was imported into sampling valve 12 as mentioned above, measured needed sample (step S14) according to the subitem detection kind modulation of mode determination.Implement to measure the mensuration operation (step S16) of sample then.Such as, when subitem detection kind is set at " 7 ", the various mensuration samples that preparation HGB, WBC/BASO, DIFF, RET, NRBC, RBC/PLT use.Measured with the mensuration sample by leucocyte detecting device 41 couples of WBC/BASO, DIFF, RET, NRBC then, 42 couples of RBC/PLT measure with the mensuration sample by the RBC/PLT detecting device, and 43 couples of HGB measure with the mensuration sample by the HGB detecting device.At this moment, leucocyte detecting device 41 only is provided with one, and therefore, NRBC, WBC/BASO, DIFF, RET respectively measure sample and import leucocyte detecting device 41 successively by the order of NRBC, WBC/BASO, DIFF, RET, measure item by item.In service in this mensuration, exerciser 62 is drawn distribution of particles figure (scatter diagram, histogram).At this, just the process according to DIFF mensuration gained optical information drafting scatter diagram describes.Exerciser 62 is a characteristic parameter with side scattered light and the side direction fluorescence signal in the light harvesting signal of being exported by leucocyte detecting device 41 in DIFF measures, and draws two-dimentional scatter diagram (distribution of particles figure).This scatter diagram (to call the DIFF scatter diagram in the following text) is X-axis, is that Y-axis is drawn with the side direction fluorescence intensity with the lateral scattering light intensity, general " erythrocyte ghost population ", " lymph population ", " monokaryon population ", " neutrophilia+basophilla population " and " acidophil granules subgroup " of occurring.These population are discerned by handling the DIFF scatter diagram by data analysis unit 64.
Then, carry out analyzing and processing (step S18) according to measuring gained distribution of particles figure.In this analyzing and processing, the DIFF scatter diagram that exerciser 62 was drawn when the data analysis unit 64 dialogue cell detection devices 41 of microcomputer 6 were measured DIFF mensuration sample is categorized as: four leucocyte groups shown in Figure 12 (lymphocyte populations, monocyte group, neutrophilia+basicyte group and acidophic cell group) and erythrocyte ghost group.In the analyzing and processing of present embodiment, the distance between each particle divided from scatter diagram and the centre of gravity place of each group can obtain the degree of membership of each particle to each group.Be divided into each group according to each particle of these degree of membership.This method for classifying particles is put down on the 5-149863 communique in patent disclosure and is documented.Measure on the gained scatter diagram at WBC/BASO, be categorized as basicyte group, basicyte leucocyte group and erythrocyte ghost group in addition.The result who the result (with reference to Figure 12) and the WBC/BASO scatter diagram analyzing and processing of leucocyte four classification and counting is classified and counted leucocyte two according to DIFF scatter diagram analyzing and processing carries out five classification to the contained leucocyte of blood preparation again.Particularly, data analysis unit 64 deducts WBC/BASO scatter diagram analyzing and processing gained " blood cell count of basicyte " from DIFF scatter diagram analyzing and processing gained " blood cell count of neutrophil(e) cell+basicyte ", can draw neutrophil's the blood cell count and the blood cell count of basicyte respectively.In view of the above, leucocyte is obtained every blood cell count by five classification (lymphocyte, monocyte, neutrophil(e) cell, basicyte and acidophic cell).In addition, in RBC/PLT measures, detect the histogrammic curve valley of one dimension of the characteristic information drafting that records according to detecting device 42, to red blood cell and blood platelet classification.The analysis result of so obtaining outputs on the display 302 of data processing equipment 3 (step S20).
On the other hand, if microcomputer 6 receives when specifying mode determination to be the input of humoral determination pattern as mentioned above at step S5, set and carry out the parameter (service condition) of humoral determination as (step S8) such as used reaction warehouse, minute settings.When in the present embodiment, minute is blood measuring as described later three times.
When switching to the humoral determination pattern (step S9), determinator 2 beginning presequences are handled (step S10) to mode determination by other mode determinations (is the blood measuring pattern at this).Series processing is to prepare for humoral determination before this.What measure under the humoral determination pattern is the low sample of haemocyte components and concentration, therefore, when blood measuring pattern (being shown as " 1: routine " among Fig. 8) switching is set at the humoral determination pattern, to carry out presequence and handle, can not have influence on the humoral determination result to guarantee background.
Presequence is handled and is comprised blank the detection.Blank in series processing before this detects the blank that criterion carried out in than determination of blood cell pattern, and to detect the criterion of (after such as switch power supply and carry out after cleaning automatically) stricter, and the value of setting is number below/.In addition, when setting is the blood measuring pattern by the humoral determination mode switch,,, a presequence do not carry out so handling because background influence (influence of residue) does not generally involve the blood measuring result.When in the humoral determination pattern, measuring humoral specimen repeatedly,, do not handle so do not carry out presequence because can not be subjected to the influence of background usually yet.But humoral specimen also has contains a large amount of particles, therefore, when the humoral specimen analysis result exceeds certain value, can occur on the interface that " measurement result is too high, might influence next sample and measure, and will carry out blank detection.Please by " affirmation "." etc. information, the notifying operation personnel might influence following analyzing specimen result.Operating personnel can carry out blank and detect by " affirmation " button.At this moment, the interface is provided with " termination " button, and as long as operating personnel also can not carry out blank and detect by " termination " button, move to standby interface.Do not detect if carry out blank, then preferably to measurement result mark symbol with a low credibility.Do like this and append blank the detection when can only be defined in necessity, with the waste of time of preventing and reagent class.
The process flow diagram of the presequence treatment step that Fig. 9 implements when the blood measuring mode switch is the humoral determination pattern for mode determination.Cellanalyzer 1 is by implementing blank detect (step S31) at determinator 2 mensuration blank samples, and microcomputer 6 compares measurement result and certain allowable value, judges whether measurement result is lower than allowable value (step S32).When measurement result was lower than allowable value, microcomputer 6 finished the presequence operation, recovered to handle.When measured value during greater than allowable value, microcomputer 6 judges whether to have carried out blank detect (the step S33) of stipulated number (such as three times), if the blank number of times that detects does not reach stipulated number, then returns step S31, implements blank the detection in the afore mentioned rules number of times once more.If blank detection assay result is not lower than allowable value yet in stipulated number, then on display operation part 7, show blank determination result and the picture (step S34) that comprises " affirmation " button, " the blank detection " button, " cleaning automatically " button.If operating personnel are by " affirmation " button (step S35), then microcomputer 6 finishes the presequence operation, recovers to handle.If by " blank detect " button (step S36), then microcomputer 6 turns back to step S31 with processing and carries out blank detection once more.If by " cleaning automatically " button (step S37), then microcomputer 6 is implemented to clean back (step S38) automatically with special-purpose cleaning fluid, and processing is turned back to step S31, carry out blank once more and detect.
After above-mentioned presequence processing finished, cellanalyzer 1 returned holding state (step S11).When operating personnel began humoral determination, the same during with the manual mensuration of blood preparation, the humoral specimen that the aspirating specimen mouth 18 of determinator 2 is inserted in the specimen containers was by the beginning switch.Microcomputer 6 is received and is begun to measure indication back (step S12) and begin to inhale and move humoral specimen (step S13).
After humoral specimen was inhaled and moved, the same humoral specimen with blood preparation was imported into sampling valve 91.13 preparation RBC/PLT measure sample (step S15) by reaction warehouse.Then, measure DIFF by leucocyte detecting device 41 and measure sample, measure RBC/PLT by RBC/PLT detecting device 42 and measure sample (step S17).Under the state of humoral determination pattern, only be DIFF mensuration sample what leucocyte detecting device 41 was measured, therefore,, finish mensuration in the shorter time in the time of also may be than blood measuring even minute is longer than the minute of blood measuring pattern.So, prolong longlyer, can improve the analysis precision of the low humoral specimen of particle concentration than the minute of blood measuring by minute with humoral determination.Minute is long more, and the population of counting will be many more, measures precision and will improve.But minute is long, and the sample disposal ability can descend, and will measure sample delivery limited in one's ability to the syringe pump of leucocyte detecting device 41 simultaneously, is appropriate with 2～6 times therefore.When the minute during in the present embodiment, with the humoral determination pattern is set at the blood measuring pattern 3 times.
On the other hand, it all is to import resistance-type detecting device 41 under any mode determination that RBC/PLT measures sample, measures under certain a fluid stream condition.Carry out analyzing and processing (step S19) according to measuring the gained characteristic information then, analysis result outputs to the display 302 (step S21) of data processing equipment 3.In the analyzing and processing under the blood measuring pattern, analyze DIFF scatter diagram etc., calculate five kinds of leucocyte subclass (neutrophil cell: NEUT, lymphocyte: LYMPH, monocyte: MONO, acidophil: EO, basocyte: information BASO) (quantity and ratio), but in the analyzing and processing under the humoral determination pattern, because blood cell count seldom or be subjected to breakage sometimes, therefore, the formal classification with the part integration is two kinds of subclass (monocyte: MN, apocytes: PMN).Lymphocyte and monocyte belong to monocyte, and neutrophil(e) cell, acidophic cell and basicyte belong to apocyte.Algorithm illustrated in this sorting algorithm and the analyzing and processing under the blood measuring pattern is identical, the Therefore, omited explanation.
Then, the analysis result obtained at step S19 and allowable value (decide threshold values) are compared (step S22).The allowable value of using during blank during the presequence of this allowable value and step S10 is handled detects is same value.When analysis result during greater than allowable value (selecting "Yes" among the step S22), then in step S23, show the blank affirmation interface of detecting 151 of beginning shown in Figure 17.This confirms to show on the interface 151: show that " measurement result is too high, might influence following sample and measure.To carry out blank detects.Please by " affirmation "." information demonstration place 152, ACK button 153 and the cancel button 154 of information.Next, what judge user's input is ACK button 153 or cancel button 154 (step S24), if input is ACK button (choosing " affirmation " in step S24), then implements blank detect (step S25).When the analysis result of obtaining at step S19 during less than allowable value (S22 selects "No" in step) or input be cancel button the time (choosing " cancellation " in step S24), then do not carry out the blank detection, return the processing of step S5.
In body fluid samples, there is haemocyte unusual particle (macrophage and middle chrotoplast, tumour cell etc.) in addition sometimes.Exist the situation of these unusual particles rarely found in the cerebrospinal fluid, but more common in other body fluid hydrothorax and the ascites.Therefore, no matter the body fluid kind how, accurately classify to the haemocyte in the body fluid and count, will get rid of the influence of these unusual particles.Therefore, the present invention is based on this new knowledge of DIFF scatter diagram upside that unusual particle appears at this cellanalyzer, instrument can be measured more accurately as the leucocyte in the body fluid samples of target.This point is not consider in aforesaid conventional art.
Figure 10 measures under the humoral determination pattern for present embodiment cellanalyzer 1, analyzes by body fluid and leucocyte and measure the mode chart of measuring the scatter diagram that sample obtained with the DIFF of reagent preparation.The longitudinal axis of scatter diagram is represented side direction fluorescence intensity (by last, fluorescence intensity is strong more more), and transverse axis is represented lateral scattering light intensity (keep right more, scattered light intensity is strong more).The weak area L F of the fluorescence intensity of scatter diagram is distributed with the erythrocyte ghost Gc that haemolysis produces, and the regional HF that fluorescence intensity is strong is distributed with unusual particles such as middle chrotoplast, and zone line MF is distributed with monocyte Mc, multinuclear leucocyte Pc.Therefore, in the analysis of scatter diagram, be that leucocyte is analyzed with the particle composition that is distributed in the regional MF except that area L F and HF, be categorized as above-mentioned two classes, and counting.In addition, comprise lymphocyte and monocyte among the monocyte Mc, comprise neutrophil cell, acidophic cell and basicyte among the multinuclear leucocyte Pc.
So during the leucocyte in the analysing body fluid, also sometimes in the body fluid contained blood cell count, be that monocyte and multinuclear leucocyte are counted therefore seldom or impaired with leukocyte differential count as significant information clinically.
In addition, there is haemocyte unusual particle (macrophage and middle chrotoplast, tumour cell etc.) in addition in the body fluid sometimes.Exist the situation of these unusual particles rarely found in the cerebrospinal fluid, but more common in other body fluid hydrothorax and the ascites.In the scatter diagram of Figure 10, the karyocyte beyond this leucocyte is distributed in regional HF.In the present embodiment, therefore karyocyte and the leukocyte differentiation beyond the leucocyte, also can be able to be obtained correct leukocyte count even contain this leucocyte karyocyte in addition in the body fluid.By the cell that appears at regional HF is counted, the degree that can provide abnormal cell to occur.In the present embodiment, each cell is divided into area L F, MF and HF according to distinguishing each regional threshold values, also can this threshold values of manual change.
Figure 11 is for showing the appropriateness of above-mentioned scatter diagram analytic approach, and relatively adopts the cellanalyzer 1 income analysis result and the accompanying drawing that adopts counter point gained count results of present embodiment.Tested sample is a hydrothorax, leukocyte count (WBC) and other unusual populations (Others) that the cellanalyzer 1 of " this law " expression present embodiment among the figure calculates, the result that " Ref " expression counter point (cell count pond direct count method (Fuchs-Rosenthal plate) and site spin method) calculates.Example 1,2,3 all is to analyze the result that a large amount of hydrothorax that occur of unusual particle are arranged, and as can be seen, has correlationship between the cellanalyzer 1 income analysis result of present embodiment and the counter point.
Figure 13 is for as being presented at picture 100 on data processing equipment 3 displays 302 by the above-mentioned DIFF of blood preparation with the analysis result of mensuration sample.The mark this shop viewing area that shows mark this shop 101 is arranged at the top of picture 100, and its next door is provided with the attribute display district that shows patient's attribute.The attribute display district specifically shows mark this shop, patient ID, patient's name, birthdate, sex, ward, the doctor in charge, mensuration date, minute and remarks etc.Bottom, attribute display district is provided with the measurement result viewing area that shows measurement result.The measurement result viewing area constitutes by several pages, and these pages or leaves can come display frame by selecting several labels 102.Label has several at homepage, chart picture and sundry item.Display frame when Figure 12 selects for the chart label.The left-half of measurement result viewing area is provided with the measured value viewing area 103 of the measured value that shows measurement result and shows the chart viewing area 104 of chart, and right half part is provided with the distribution plan viewing area 105 of the distribution plan that shows measurement result.The measured value viewing area show WBC, RBC ..., NEUT# ... BASO#, NEUT% ..., project, data and unit such as BASO%, chart viewing area 104 shows the mark result that the sample that can be used as useful information in the clinical examination is unusual and disease is suspected about WBC, PLT, RBC or RET.
Distribution plan viewing area 105 shows six distribution plans.The scatter diagram of upper left quarter is the DIFF scatter diagram.Upper right quarter is WBC/BASO with, middle part, a left side is juvenile cell (IMI) usefulness, and right middle is each scatter diagram that RET uses.Lower left quarter is the RBC histogram, and right lower quadrant is the PLT histogram.
Figure 14 is for as being presented at picture 110 on data processing equipment 3 displays 302 by the above-mentioned DIFF of body fluid preparation with the measurement result of mensuration sample.The mark this shop viewing area 111 that shows mark this shop is arranged at the top of picture 110, and its next door is provided with patient's attribute display district.The left side of mark this shop viewing area 111 shows " F " that expression is measured with the humoral determination pattern.Can recognize clearly that in view of the above this analysis result is the humoral determination result.Several pages of being selected by available label 112 in measurement result viewing area constitute.In this example, selected the label of " humoral determination (body fluid) ".
On measured value viewing area 113, the body fluid different with the measurement result of blood measuring pattern is with measuring entry name WBC-BF (WBC number), RBC-BF (RBC number), MN# (monocyte number (lymphocyte+unicellular)), PMN# (multi-nucleus cell number (neutrophil cell+basicyte+acidophil)), MN% (the monocyte ratio in the leucocyte), PMN% (the apocyte ratio in the leucocyte) and measured value, unit corresponding demonstration respectively.Also be provided with chart viewing area 114 equally at humoral determination with blood measuring.The distribution plan viewing area shows two distribution Figure 115, and the top scatter diagram is the DIFF scatter diagram.The bottom is divided into the RBC histogram.
Figure 15 is for having selected " the illustration of retrieval BF (Research (BF)) label in label 112 in Figure 14 picture 110.This picture also shows the project same with picture 110 except that showing search argument viewing area 116.Show in the search argument viewing area 116 population be present in as shown in figure 10 in the population " HF-BF# " of regional HF, the regional HF and the population that is present in the zone that comprises regional HF and regional MF ratio " HF-BF% ", be present in the population " TC-BF# " in the zone that comprises regional HF and regional MF.In addition, " HF-BF% " is HF-BF and the ratio of TC-BF.
Figure 16 is the storage sample guide look display frame 140 that is presented on data processing equipment 3 displays 302.The 130th, patient's attribute display district.Its top is provided with the measurement result viewing area of selecting to show measurement result by label.Measurement result viewing area leftmost column 131 is used to show that the checking work of measurement result do not do or do.V represents to verify.Its right row 132 are used to show mode determination.The measurement result of " F " expression humoral determination pattern.Though if be to need the blank high value sample that detects under the humoral determination pattern, do not carry out blank the detection, for it is showed, mark can reverse F.
More than with regard to the 26S Proteasome Structure and Function of cellanalyzer of the present invention, with the cellanalyzer of packing in advance is that example is illustrated, but also can realize this function by control system, with this control system traditional cellanalyzer of packing into, allow traditional cellanalyzer bring into play function of the present invention.
In the described structure of present embodiment, under the blood measuring pattern to specimen amount, reagent type and the amount of reagent during the formation determination sample is all the same separately to leukocyte differential count under leukocyte differential count and the humoral determination pattern.Can be not limited thereto, also can allow prepare specimen amount and the amount of reagent that classification leucocyte is used the mensuration sample respectively with the specimen amount and the amount of reagent of mensuration sample under the humoral determination pattern more than classification leucocyte under the preparation blood measuring pattern.Because it is longer than blood measuring pattern under the humoral determination pattern to the leukocyte differential count minute, it is also many to measure required mensuration sample size, therefore, doing respectively like this, the leukocyte differential count under leukocyte differential count under the blood measuring pattern and humoral determination pattern prepares an amount of mensuration sample.
In the present embodiment, with regard to scattered light and fluorescence structure under the humoral determination pattern to leukocyte differential count set forth, but be not limited thereto, also can use such as scattered light and absorbing light under the humoral determination pattern to leukocyte differential count.Light absorbing mensuration can be sneaked into sample with other reagent with the coloring agent of stain leukocytes, the formation determination sample should be measured sample and offer flow cell, made it to form in flow cell sample stream, this sample stream of illumination receives the light that sample stream is sent by light collecting elements such as photodiodes.When leucocyte passed through in the flow cell, light was absorbed by leucocyte, and its degree of absorption can be used as the light harvesting amount of light collecting element and caught.About this light absorbing mensuration, deliver on No. 5138181 communique of No. the 5122453rd, United States Patent (USP) and United States Patent (USP).Also can measure resistance and replace scattered light, come leucocyte is classified by resistance value and absorbing light.
Claims (20)
1. cellanalyzer of measuring blood comprises:
The mode determination setup unit is used to set the humoral determination pattern;
Measure the beginning indicating member, be used to accept the indication that begins to measure;
The optical information acquiring unit, sample is measured in illumination, obtains optical information from the contained cell of this mensuration sample;
Analytic unit, behind the described humoral determination mode initialization, when described mensuration begins indicating member when receiving the indication that begins to measure, the contained cell of sample be will measure according to the described optical information of obtaining in the described mensuration sample of measuring by humoral specimen and leucocyte with reagent preparation and leucocyte and leucocyte karyocyte in addition will be categorized as at least, and to the counting of the karyocyte beyond leucocyte and the leucocyte.
2. cellanalyzer according to claim 1 is characterized in that: described analytic unit is divided into multinuclear leucocyte and monocyte with leucocyte, respectively to multinuclear leucocyte and monocyte counting.
3. cellanalyzer according to claim 2 is characterized in that: described analytic unit calculates multinuclear leucocyte shared ratio or monocyte shared ratio in leucocyte in leucocyte.
4. cellanalyzer according to claim 1 is characterized in that: obtain full karyocyte number the karyocyte number of described analytic unit beyond leukocyte count and leucocyte, obtain the leucocyte karyocyte in addition and the ratio of full karyocyte again.
5. cellanalyzer according to claim 1 is characterized in that: described analytic unit is further told erythrocyte ghost with the contained cell of described mensuration sample.
6. cellanalyzer according to claim 1, it is characterized in that: when not setting described humoral determination pattern, after the indication that mensuration beginning indicating member is accepted to begin to measure, analytic unit is several subclass according to the described optical information of obtaining the mensuration sample with reagent preparation from blood preparation and leucocyte mensuration with the contained leukocyte differential count of described mensuration sample, and counting.
7. cellanalyzer according to claim 1 is characterized in that: also possess output unit, be used to export the display frame of the analysis result that shows described analytic unit.
8. cellanalyzer according to claim 1 is characterized in that: described optical information is selected from scattered light information, the fluorescence information that cell sends, the light absorption information of cell extinction and the combination of these information that cell sends.
9. cellanalyzer according to claim 1 is characterized in that: described humoral specimen is selected from the dislysate that comprises cerebrospinal fluid, hydrothorax, ascites, pericardium liquid, joint fluid, peritoneal dialysis and the liquid of intraperitoneal cleaning fluid.
10. cellanalyzer according to claim 1 is characterized in that: described karyocyte is selected from by macrophage, middle chrotoplast, tumour cell, erythrocyte ghost and the colony that constitutes thereof.
11. a cellanalyzer comprises:
The mode determination setup unit is used to set the humoral determination pattern;
Measure the beginning indicating member, be used to accept the indication that begins to measure;
The aspirating specimen unit is used for inhaling and moves sample;
Measure the specimen preparation unit, inhale the sample and the leucocyte mensuration of moving with the aspirating specimen unit and measure sample with reagent preparation;
The optical information acquiring unit, sample is measured in illumination, obtains optical information from the contained cell of this mensuration sample;
Analytic unit according to the described optical information of obtaining, is classified to the contained cell of described mensuration sample, and the described cell count to classifying;
After described humoral determination pattern is set by described mode determination setup unit, begin indicating member when receiving the indication that begins to measure in described mensuration, described mensuration specimen preparation unit is inhaled the humoral specimen and the described leucocyte that move with described aspirating specimen unit and is measured with the described mensuration sample of reagent preparation, described analytic unit is according to the described optical information of obtaining from described mensuration sample, contained cytological classification is leucocyte and leucocyte cell in addition in the sample with measuring, and to the counting of the karyocyte beyond leucocyte and the leucocyte.
12. cellanalyzer according to claim 11, it is characterized in that: when not setting described humoral determination pattern, after the indication that mensuration beginning indicating member is accepted to begin to measure, described mensuration specimen preparation unit is inhaled the blood preparation and the described leucocyte mensuration of moving with described aspirating specimen unit and is measured sample with reagent preparation, described analytic unit is several subclass according to the described optical information of obtaining from described mensuration sample with the contained leukocyte differential count of described mensuration sample, and counting.
13. a method for analyzing body fluid comprises:
(a) step: set mode determination, so that set the humoral determination pattern;
(b) step: behind the humoral determination mode initialization, accept the indication that begins to measure;
(c) step: after accepting the described indication that begins to measure, measure the mensuration sample of using reagent preparation by humoral specimen and leucocyte, from the contained cell of this mensuration sample, obtain optical information with rayed;
(d) step: according to the described optical information of obtaining, the contained cell of described mensuration sample is categorized as leucocyte and leucocyte karyocyte in addition at least, and to the counting of the karyocyte beyond leucocyte and the leucocyte.
14. method for analyzing body fluid according to claim 13, it is characterized in that: also comprise (e) step: after accepting the described indication that begins to measure, suction moves described humoral specimen, and is measured with the described mensuration sample of reagent preparation by described humoral specimen and described leucocyte that suction moves.
15. according to claim 13 or 14 described method for analyzing body fluid, it is characterized in that: described (d) step comprises that with leukocyte differential count be multinuclear leucocyte and monocyte and step that multinuclear leucocyte and monocyte are counted respectively.
16. method for analyzing body fluid according to claim 15 is characterized in that: described (d) step comprises the step of monocyte ratio in the multinuclear leucocyte ratio asked in the leucocyte or the leucocyte.
17. the control system of a body fluid analysis instrument comprises:
A kind of mode determination setting control system is used to set mode determination, so that set the humoral determination pattern;
Control system is accepted in the indication of a kind of mensuration, be used for the humoral determination mode initialization after, accept the indication that begins to measure;
A kind of optical information is obtained control system, be used to accept the described indication that begins to measure after, measure mensuration sample with rayed by humoral specimen and leucocyte with reagent preparation, from the contained cell of this mensuration sample, obtain optical information; And
A kind of cytological classification and counting control system are used for according to the described optical information of obtaining, and the contained cell of described mensuration sample is categorized as leucocyte and leucocyte karyocyte in addition at least, and to the counting of the karyocyte beyond leucocyte and the leucocyte.
18. the control system of body fluid analysis instrument according to claim 17 is characterized in that: described cytological classification and counting control system can be multinuclear leucocyte and monocyte with leukocyte differential count and multinuclear leucocyte and monocyte counted respectively.
19. the control system of body fluid analysis instrument according to claim 18 is characterized in that: cytological classification and counting control system can calculate monocyte ratio in multinuclear leucocyte ratio in the leucocyte or the leucocyte.
20. the control system according to the described body fluid analysis instrument of one of claim 17～19 is characterized in that: cytological classification and counting control system can further be told erythrocyte ghost from the contained cell of described mensuration sample.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610212407.XA CN105891090B (en) | 2007-02-01 | 2008-01-31 | Blood cell analyzer, body fluid analysis method, and control system therefor |
| CN201610209662.9A CN105807038B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
| CN201610209661.4A CN105866012B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
| CN201610208992.6A CN105807037B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-022524 | 2007-02-01 | ||
| JP2007022524 | 2007-02-01 | ||
| JP2007022524 | 2007-02-01 | ||
| JP2007119012A JP4926812B2 (en) | 2007-02-01 | 2007-04-27 | Blood cell analyzer and body fluid analysis method |
| JP2007-119012 | 2007-04-27 | ||
| JP2007119012 | 2007-04-27 |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610209661.4A Division CN105866012B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
| CN201610212407.XA Division CN105891090B (en) | 2007-02-01 | 2008-01-31 | Blood cell analyzer, body fluid analysis method, and control system therefor |
| CN201610208992.6A Division CN105807037B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
| CN201610209662.9A Division CN105807038B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101236195A true CN101236195A (en) | 2008-08-06 |
| CN101236195B CN101236195B (en) | 2016-05-04 |
Family
ID=39785791
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610212407.XA Active CN105891090B (en) | 2007-02-01 | 2008-01-31 | Blood cell analyzer, body fluid analysis method, and control system therefor |
| CN200810005239.2A Active CN101236195B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and control system thereof |
| CN201610209662.9A Active CN105807038B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
| CN201610208992.6A Active CN105807037B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610212407.XA Active CN105891090B (en) | 2007-02-01 | 2008-01-31 | Blood cell analyzer, body fluid analysis method, and control system therefor |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610209662.9A Active CN105807038B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
| CN201610208992.6A Active CN105807037B (en) | 2007-02-01 | 2008-01-31 | Cellanalyzer, method for analyzing body fluid and its control system |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4926812B2 (en) |
| CN (4) | CN105891090B (en) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102331397A (en) * | 2011-07-08 | 2012-01-25 | 无锡荣兴科技有限公司 | Photoelectric sensor for statistic analysis of blood cells |
| CN103364314A (en) * | 2012-03-30 | 2013-10-23 | 希森美康株式会社 | Sample analyzer |
| CN103436439A (en) * | 2013-09-06 | 2013-12-11 | 朱耀辉 | Calibration method for cell counter based on image identification method |
| CN103702735A (en) * | 2011-05-20 | 2014-04-02 | 西门子公司 | Arrangement and process for optical analysis and specific isolation of biological samples |
| CN104237542A (en) * | 2008-09-03 | 2014-12-24 | 株式会社日立高新技术 | Automatic analyzer |
| CN104535298A (en) * | 2014-12-29 | 2015-04-22 | 中国科学院长春光学精密机械与物理研究所 | Lateral scattering light simulator applied to imaging flow cytometer |
| CN104805004A (en) * | 2014-01-29 | 2015-07-29 | 希森美康株式会社 | Blood cell analyzer |
| CN104949944A (en) * | 2014-03-31 | 2015-09-30 | 希森美康株式会社 | Blood analyzer |
| WO2018148942A1 (en) * | 2017-02-17 | 2018-08-23 | 深圳迈瑞生物医疗电子股份有限公司 | Blood cell analysis method, and blood cell analysis instrument |
| WO2019041270A1 (en) * | 2017-08-31 | 2019-03-07 | 深圳迈瑞生物医疗电子股份有限公司 | Sample testing device, sample analyzer, and sample testing method |
| CN109991430A (en) * | 2017-12-30 | 2019-07-09 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analyser and method of sample analysis |
| CN110366683A (en) * | 2017-03-07 | 2019-10-22 | 株式会社日立高新技术 | Automatic analysing apparatus |
| WO2019206297A1 (en) * | 2018-04-28 | 2019-10-31 | 深圳迈瑞生物医疗电子股份有限公司 | Blood analyzer and analysis method |
| CN113959912A (en) * | 2020-07-20 | 2022-01-21 | 深圳迈瑞生物医疗电子股份有限公司 | Leukocyte detection method and reagent for resisting platelet aggregation interference and application thereof |
| WO2022061674A1 (en) * | 2020-09-24 | 2022-03-31 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analyzer, sample analysis method, and computer-readable storage medium |
| CN114791502A (en) * | 2022-06-13 | 2022-07-26 | 深圳市帝迈生物技术有限公司 | Sample detection method and sample analyzer |
| WO2023028835A1 (en) * | 2021-08-31 | 2023-03-09 | 深圳迈瑞动物医疗科技股份有限公司 | Specimen analysis apparatus and specimen analysis method |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6106113B2 (en) * | 2013-02-28 | 2017-03-29 | シスメックス株式会社 | Urine sample analyzer, sample analysis method, and sample analysis control program |
| US9566605B2 (en) | 2015-01-20 | 2017-02-14 | R.J. Reynolds Tobacco Products | Humidity control insert for cigarette packs |
| JP6680492B2 (en) | 2015-09-11 | 2020-04-15 | シスメックス株式会社 | Cell analyzer and cell analysis method |
| JP7002245B2 (en) | 2017-08-10 | 2022-01-20 | シスメックス株式会社 | Blood analyzers, blood analysis methods and programs |
| JP6434114B1 (en) * | 2017-11-30 | 2018-12-05 | シスメックス株式会社 | Measuring method and measuring device |
| US11538566B2 (en) * | 2018-05-23 | 2022-12-27 | Beckman Coulter, Inc. | Sample analysis with test determination based on identified condition |
| CN109612911B (en) * | 2018-12-26 | 2023-07-21 | 深圳天依生命健康科技有限公司 | Full-automatic sperm cell detector |
| CN112654857B (en) * | 2018-12-28 | 2024-06-07 | 深圳迈瑞生物医疗电子股份有限公司 | Method for processing detection value of measurement object, blood cell analyzer and storage medium |
| CN114450589A (en) * | 2019-10-23 | 2022-05-06 | 深圳迈瑞生物医疗电子股份有限公司 | Method for analyzing red blood cells in blood sample and blood analysis system |
| CN114829944A (en) * | 2019-12-31 | 2022-07-29 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis system and method |
| CN112304816A (en) * | 2020-10-28 | 2021-02-02 | 宁夏医科大学总医院 | Cerebrospinal fluid cell characteristic collecting method and device |
| CN113686759B (en) * | 2021-02-03 | 2023-11-24 | 深圳市帝迈生物技术有限公司 | Kit and POCT blood cell analyzer |
| CN113759129A (en) * | 2021-09-26 | 2021-12-07 | 北京倍肯恒业科技发展股份有限公司 | Rapid detection card for leucocyte-bound C-reactive protein and preparation method thereof |
| WO2023123466A1 (en) * | 2021-12-31 | 2023-07-06 | 深圳迈瑞动物医疗科技股份有限公司 | Sample analysis apparatus and sample analysis method |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3070968B2 (en) * | 1991-05-14 | 2000-07-31 | シスメックス株式会社 | Urine cell analysis reagents and methods |
| US5812419A (en) * | 1994-08-01 | 1998-09-22 | Abbott Laboratories | Fully automated analysis method with optical system for blood cell analyzer |
| JP3875754B2 (en) * | 1995-11-17 | 2007-01-31 | シスメックス株式会社 | Standard solution for flow cytometer |
| EP1166110A1 (en) * | 1999-03-31 | 2002-01-02 | Bayer Corporation | Single channel, single dilution detection method |
| US7630063B2 (en) * | 2000-08-02 | 2009-12-08 | Honeywell International Inc. | Miniaturized cytometer for detecting multiple species in a sample |
| WO2002015786A1 (en) * | 2000-08-25 | 2002-02-28 | Cytometrics, Llc | System, method and computer program product for measuring blood properties form a spectral image |
| ATE434760T1 (en) * | 2000-09-18 | 2009-07-15 | Sysmex Corp | BLOOD CELL DETECTOR, BLOOD ANALYZER AND BLOOD ANALYSIS METHOD USING THE DETECTOR |
| JP2002207035A (en) * | 2001-01-10 | 2002-07-26 | Sysmex Corp | Method for counting tumorigenic cell |
| AU2002360305A1 (en) * | 2001-10-26 | 2003-05-06 | Immunivest Corporation | Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample |
| US6653137B2 (en) * | 2001-12-03 | 2003-11-25 | Streck Laboratories Inc. | Hematology reference control |
| JP2003287491A (en) * | 2002-01-28 | 2003-10-10 | Sysmex Corp | Apparatus and method for analyzing particle |
| EP1348943A3 (en) * | 2002-03-25 | 2003-12-17 | Sysmex Corporation | Sheath liquid for particle analyzer |
| CA2428740A1 (en) * | 2002-05-20 | 2003-11-20 | Bayer Corporation | Automated method and reagent therefor for assaying body fluid samples such as cerebrospinal fluid (csf) |
| US6979550B1 (en) * | 2002-09-05 | 2005-12-27 | Rivas Ariel L | Method for diagnosis of, and determination of susceptibility to bovine mastitis |
| CN1834659A (en) * | 2005-03-17 | 2006-09-20 | 希森美康株式会社 | Sample analyzer and sample analyzing method |
| JP4873969B2 (en) * | 2005-03-17 | 2012-02-08 | シスメックス株式会社 | Sample analyzer and sample analysis method |
| US7580120B2 (en) * | 2005-04-07 | 2009-08-25 | Sysmex Corporation | Blood analyzer, sample analyzer, and flow cytometer |
| EP1744145B1 (en) * | 2005-07-12 | 2015-09-09 | Sysmex Corporation | Standard material for particle analyzer |
| JP4994920B2 (en) * | 2007-02-01 | 2012-08-08 | シスメックス株式会社 | Sample analyzer |
-
2007
- 2007-04-27 JP JP2007119012A patent/JP4926812B2/en active Active
-
2008
- 2008-01-31 CN CN201610212407.XA patent/CN105891090B/en active Active
- 2008-01-31 CN CN200810005239.2A patent/CN101236195B/en active Active
- 2008-01-31 CN CN201610209662.9A patent/CN105807038B/en active Active
- 2008-01-31 CN CN201610208992.6A patent/CN105807037B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| JOHANNES J. M. L. HOFFMANN, WILLY C. M. JANSSEN: "Automated Counting of Cells in Cerebrospinal Fluid Using the CellDyn-4000 Haematology Analyser", 《CLINICAL CHEMISTRY AND LABORATORY MEDICINE》 * |
| KATHARINA RUZICKA等: "The New Hematology Analyzer Sysmex XE-2100", 《ARCH PATHOL LAB MED》 * |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104237542A (en) * | 2008-09-03 | 2014-12-24 | 株式会社日立高新技术 | Automatic analyzer |
| CN104237542B (en) * | 2008-09-03 | 2016-11-02 | 株式会社日立高新技术 | Automatic analysing apparatus |
| CN104215785B (en) * | 2008-09-03 | 2016-01-20 | 株式会社日立高新技术 | Automatic analysing apparatus |
| CN103702735A (en) * | 2011-05-20 | 2014-04-02 | 西门子公司 | Arrangement and process for optical analysis and specific isolation of biological samples |
| CN103702735B (en) * | 2011-05-20 | 2016-11-09 | 西门子公司 | Apparatus and method for optical analysis and specific isolation biological sample |
| US9958435B2 (en) | 2011-05-20 | 2018-05-01 | Siemens Healthcare Diagnostics Inc. | Arrangement and process for optical analysis and specific isolation of biological samples |
| CN102331397A (en) * | 2011-07-08 | 2012-01-25 | 无锡荣兴科技有限公司 | Photoelectric sensor for statistic analysis of blood cells |
| CN103364314A (en) * | 2012-03-30 | 2013-10-23 | 希森美康株式会社 | Sample analyzer |
| CN103436439B (en) * | 2013-09-06 | 2014-12-17 | 朱耀辉 | Calibration device for cell counter based on image identification method |
| CN103436439A (en) * | 2013-09-06 | 2013-12-11 | 朱耀辉 | Calibration method for cell counter based on image identification method |
| CN104805004A (en) * | 2014-01-29 | 2015-07-29 | 希森美康株式会社 | Blood cell analyzer |
| CN104949944B (en) * | 2014-03-31 | 2018-10-26 | 希森美康株式会社 | Blood analysis device |
| CN104949944A (en) * | 2014-03-31 | 2015-09-30 | 希森美康株式会社 | Blood analyzer |
| CN104535298A (en) * | 2014-12-29 | 2015-04-22 | 中国科学院长春光学精密机械与物理研究所 | Lateral scattering light simulator applied to imaging flow cytometer |
| CN104535298B (en) * | 2014-12-29 | 2017-07-11 | 中国科学院长春光学精密机械与物理研究所 | Side scattered light analogue means applied to imaging flow cytometer |
| WO2018148942A1 (en) * | 2017-02-17 | 2018-08-23 | 深圳迈瑞生物医疗电子股份有限公司 | Blood cell analysis method, and blood cell analysis instrument |
| US11501852B2 (en) | 2017-02-17 | 2022-11-15 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Blood cell analysis method and blood cell analyzer |
| CN110366683A (en) * | 2017-03-07 | 2019-10-22 | 株式会社日立高新技术 | Automatic analysing apparatus |
| CN110366683B (en) * | 2017-03-07 | 2020-06-23 | 株式会社日立高新技术 | Automatic analyzer |
| US11383232B2 (en) | 2017-08-31 | 2022-07-12 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Sample testing device, sample analyzer and sample testing method |
| WO2019041270A1 (en) * | 2017-08-31 | 2019-03-07 | 深圳迈瑞生物医疗电子股份有限公司 | Sample testing device, sample analyzer, and sample testing method |
| CN109991430A (en) * | 2017-12-30 | 2019-07-09 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analyser and method of sample analysis |
| WO2019206297A1 (en) * | 2018-04-28 | 2019-10-31 | 深圳迈瑞生物医疗电子股份有限公司 | Blood analyzer and analysis method |
| EP3789757A4 (en) * | 2018-04-28 | 2021-07-07 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Blood analyzer and analysis method |
| CN111602046A (en) * | 2018-04-28 | 2020-08-28 | 深圳迈瑞生物医疗电子股份有限公司 | Blood analyzer and analysis method |
| CN111602046B (en) * | 2018-04-28 | 2024-01-09 | 深圳迈瑞生物医疗电子股份有限公司 | Blood analyzer and analysis method |
| CN113959912A (en) * | 2020-07-20 | 2022-01-21 | 深圳迈瑞生物医疗电子股份有限公司 | Leukocyte detection method and reagent for resisting platelet aggregation interference and application thereof |
| WO2022061674A1 (en) * | 2020-09-24 | 2022-03-31 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analyzer, sample analysis method, and computer-readable storage medium |
| WO2023028835A1 (en) * | 2021-08-31 | 2023-03-09 | 深圳迈瑞动物医疗科技股份有限公司 | Specimen analysis apparatus and specimen analysis method |
| CN114791502A (en) * | 2022-06-13 | 2022-07-26 | 深圳市帝迈生物技术有限公司 | Sample detection method and sample analyzer |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008209386A (en) | 2008-09-11 |
| CN105891090B (en) | 2020-01-17 |
| CN101236195B (en) | 2016-05-04 |
| CN105807038A (en) | 2016-07-27 |
| CN105807038B (en) | 2019-06-18 |
| CN105891090A (en) | 2016-08-24 |
| CN105807037B (en) | 2019-05-28 |
| CN105866012A (en) | 2016-08-17 |
| JP4926812B2 (en) | 2012-05-09 |
| CN105807037A (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101236194B (en) | Sample analyzer and control system thereof | |
| CN101236195A (en) | Hematological analyzer, method for analyzing body fluid and control system thereof | |
| US11921106B2 (en) | Sample analyzer and computer program product | |
| US20230055601A1 (en) | Urine analysis system, image capturing apparatus, urine analysis method | |
| US10168320B2 (en) | Hematological analyzer, method for analyzing body fluid and computer program product | |
| CN101358983B (en) | Diagnosis support system and device for providing diagnosis support information | |
| CN101726609B (en) | Sample analyzer | |
| CN101206218B (en) | Blood cell analyzer | |
| JP2012168192A (en) | Blood analysis apparatus and blood analysis method | |
| CN104749108B (en) | The detection method of filaria larva, blood analysis device and information processing system in blood | |
| CN105866012B (en) | Cellanalyzer, method for analyzing body fluid and its control system | |
| Muturi | Comparative assessment of automated and manual white blood cell counts at Kenyatta National Hospital Haematology Labaratory |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |